Login
$MMSI
$86.35 -$0.28 (0.32%) Live

$MMSI 8-K SEC Filings

Filed On Filing
29 Oct 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

MERIT MEDICAL REPORTS THIRD QUARTER 2026 RESULTS: DELIVERS 9% ORGANIC CONSTANT CURRENCY REVENUE GROWTH AND RAISES FULL-YEAR 2026 GUIDANCE

20 Aug 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Employment Agreement Page 1 of 15 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Merit Medical Systems, Inc., a Utah corporation (the “Company”), and Sheri Lewis (the “Executive”)...

30 Jul 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 9% and up 9%, respectively

19 May 2026 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

The Corporation may have such offices, either within or without the State of Utah, as the Board of Directors may designate or as the business of the Corporation may require from time to time. The registered office and principal office of...

30 Apr 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 5% and up 3%, respectively

13 Apr 2026 8-K: Regulation FD Disclosure

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished by Merit Medical Systems, Inc. (“Merit”) to provide historical revenue information disaggregated by its new foundational and therapeutic product...

01 Apr 2026 8-K: Regulation FD Disclosure

SOUTH JORDAN, Utah, April 1, 2026 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced it has acquired View Point Medical, Inc. (View Point). Through a merger transacti...

24 Feb 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 10% and up 7%, respectively

08 Jan 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Merit Medical Appoints F. Ann Millner as Chair of the Board and Announces Projected Preliminary Unaudited Revenue Results for the Fourth Quarter of 2025

13 Nov 2025 8-K: Regulation FD Disclosure

Merit Medical Provides Update on U.S. Reimbursement and Commercial Strategies for WRAPSODY® Cell-Impermeable Endoprosthesis.

03 Nov 2025 8-K: Regulation FD Disclosure

On October 17, 2025, Merit Medical Systems, Inc. (“Merit”) filed a Current Report on Form 8-K and related press release announcing it signed a definitive asset purchase agreement with Pentax of America, Inc., a subsidiary of PENTAX® Medi...

30 Oct 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectively

17 Oct 2025 8-K: Regulation FD Disclosure

Asset acquisition would expand Merit’s Endoscopy portfolio with an innovative device to treat patients suffering from Barretts esophagus and other gastrointestinal disorders.

10 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation

On October 3, 2025, the Board of Directors (the “Board”) of Merit Medical Systems, Inc. (“Merit”), in connection with the previously announced resignation of Fred P. Lampropoulos as Merit’s President and Chief Executive Officer (“CEO”) a...

30 Jul 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 6.7%, respectively

11 Jul 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Fred Lampropoulos will continue to serve as Chairman of Merit’s Board of Directors

20 May 2025 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide range of procedures Merit’s portfolio supports.

19 May 2025 8-K: Submission of Matters to a Vote of Security Holders

On May 14, 2025, Merit Medical Systems, Inc. (the “Company”) held its 2025 Annual Meeting of Shareholders (the “Annual Meeting”). A total of 59,067,132 shares of the Company’s common stock were entitled to vote at the Annual Meeting as o...

24 Apr 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 10.9% and up 6.0%, respectively

25 Feb 2025 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectively

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support